/
PHAT
$9.18+$0.01 (+0.11%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$741.9M
81M shares
52-week range
$8.21 – $18.31
10% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Change$-22.62
Phathom Pharmaceuticals, Inc. Common Stock
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
www.phathompharma.com- Employees
- 371
- IPO / List date
- Oct 25, 2019
- HQ
- FLORHAM PARK, NJ
Held by traders on TradeandTell
No one on the platform currently holds PHAT.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 305,800 | $3.4M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded PHAT yet.
